NEW YORK, April 19  - Rosetta Inpharmatics reported $4.7 million in revenues for the first quarter of 2001 Thursday, up from $548,000 for the first quarter of 2000, while losses were narrower than Wall Street's expectations.

The Kirkland, Wash., bioinformatics company attributed the revenue surge to a collaboration with Monsanto in crop gene expression that the companies initiated at the end of November 2000, and to sales of the Rosetta Resolver system. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.